92 related articles for article (PubMed ID: 598751)
1. Inhibition of the fibrinolytic system in Behçet's disease?
Asbeck F; Meyer-Boernecke D; van de Loo J
Haemostasis; 1977; 6(5):303-9. PubMed ID: 598751
[TBL] [Abstract][Full Text] [Related]
2. Studies on the blood fibrinolytic enzyme system of patients with cutaneous vasculitis.
Toki N; Yamura T
Br J Dermatol; 1980 Jul; 103(1):41-50. PubMed ID: 6775670
[TBL] [Abstract][Full Text] [Related]
3. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
4. Factual or artificial inhibition of fibrinolysis and the occurrence of venous thrombosis in 3 cases of Behçet's disease.
Kluft C; Michiels JJ; Wijngaards G
Scand J Haematol; 1980 Nov; 25(5):423-30. PubMed ID: 6452679
[TBL] [Abstract][Full Text] [Related]
5. Coagulation and fibrinolytic activity in Behçet's disease.
Hampton KK; Chamberlain MA; Menon DK; Davies JA
Thromb Haemost; 1991 Sep; 66(3):292-4. PubMed ID: 1745999
[TBL] [Abstract][Full Text] [Related]
6. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms.
Aitchison R; Chu P; Cater DR; Harris RJ; Powell RJ
Ann Rheum Dis; 1989 Jul; 48(7):590-3. PubMed ID: 2505697
[TBL] [Abstract][Full Text] [Related]
7. Haemostatic markers of procoagulant imbalance in Behçet's disease.
Haznedaroğlu IC; Ozcebe O; Celik I; Dündar SV; Kirazhi S
Eur J Haematol; 1996 Jul; 57(1):107-8. PubMed ID: 8698121
[No Abstract] [Full Text] [Related]
8. Plasminogen activator activity levels in patients with Behçet's syndrome.
Mishima H; Masuda K; Shimada S; Toki N; Tsushima H; Gocho M
Arch Ophthalmol; 1985 Jul; 103(7):935-6. PubMed ID: 4040357
[TBL] [Abstract][Full Text] [Related]
9. [Parameters of hemostasis in Behçet's disease].
Dupuy E; Tobelem G; Bourgeois P; Soria C; Pellerin A; Bellucci S; Caen JP
Rev Med Interne; 1983 Dec; 4(4):317-21. PubMed ID: 6665348
[TBL] [Abstract][Full Text] [Related]
10. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
Aoki N; Moroi M; Matsuda M; Tachiya K
J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma granulocyte elastase levels in Behçet's disease.
Tsutsui K; Hasegawa M; Takata M; Takehara K
J Rheumatol; 1998 Feb; 25(2):326-8. PubMed ID: 9489828
[TBL] [Abstract][Full Text] [Related]
12. [Proteinase inhibitors and fibrinogen split products in patients with malignant diseases (author's transl)].
Schwarz HP; Aiginger P; Kuzmits R
Acta Med Austriaca; 1981; 8(1):22-5. PubMed ID: 6165218
[TBL] [Abstract][Full Text] [Related]
13. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
Aoki N; Moroi M; Tachiya K
Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
[TBL] [Abstract][Full Text] [Related]
14. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
Ries M; Klinge J; Rauch R; Keuper H; Harms D
Biol Neonate; 1996; 69(5):298-306. PubMed ID: 8790908
[TBL] [Abstract][Full Text] [Related]
15. Fibrin formation and dissolution in women receiving oral contraceptive drugs.
Ball AP; McKee PA
J Lab Clin Med; 1977 Apr; 89(4):751-62. PubMed ID: 845477
[TBL] [Abstract][Full Text] [Related]
16. Release of fibrinopeptides from fibrinolytic fibrinogen fragment E.
Peyer A; Straub PW
Thromb Diath Haemorrh; 1973 May; 29(2):300-12. PubMed ID: 4271587
[No Abstract] [Full Text] [Related]
17. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
18. [Subclinical pro-thrombotic state in a relapse of Behcet's disease--case report].
Undas A; Pinis G
Pol Arch Med Wewn; 1996 Sep; 96(3):258-62. PubMed ID: 9122017
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous fibrinolytic potential, tPA dependent, is reduced in Behçet's disease.
Lotti T; Matucci-Cerinic M
Br J Dermatol; 1989 Dec; 121(6):713-6. PubMed ID: 2514783
[TBL] [Abstract][Full Text] [Related]
20. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
